Equities

Cuorips Inc

4894:TYO

Cuorips Inc

Actions
  • Price (JPY)9,720.00
  • Today's Change370.00 / 3.96%
  • Shares traded670.60k
  • 1 Year change+394.66%
  • Beta--
Data delayed at least 20 minutes, as of Sep 20 2024 04:42 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cuorips Inc is a Japan-based company mainly engaged in the development and commercialization of regenerative medical products and contract development and manufacturing organization (CDMO) business. The main product of the Company is human iPS cell-derived cardiomyocyte sheets. The Company provides regenerative medical products for the heart and other areas through in-house research, joint research with universities and other research institutions and major pharmaceutical companies. The Company operates CDMO business using CLiC-1, a commercial cell culture and processing facility with an integrated laboratory based on the Company's original design concept.

  • Revenue in JPY (TTM)19.39m
  • Net income in JPY-657.94m
  • Incorporated2017
  • Employees59.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Eyepoint Pharmaceuticals Inc7.17bn-12.35bn67.85bn121.00--2.04--9.46-1.80-1.801.084.380.20161.108.18416,454.50-34.74-40.44-47.07-47.7991.3583.45-172.29-186.234.69--0.00--11.14--30.77------
Sinotherapeutics Inc8.18bn1.86bn67.85bn260.0036.532.76--8.300.20390.20390.8982.700.30062.646.401,565,771.006.83--7.36--51.48--22.71--10.69--0.00004--21.13---34.29------
Gufic BioSciences Ltd13.85bn1.47bn68.07bn1.45k45.89--38.694.918.708.7081.95--------5,624,707.00--11.46--19.2152.3945.7910.6010.46--8.09--1.3116.8018.128.0731.4653.8314.87
Cuorips Inc19.39m-657.94m70.22bn59.00--12.04--3,622.01-88.11-88.112.60729.160.00321.1510.60328,610.20-10.89---11.14--44.66---3,394.40--35.37--0.00---39.65---39.84------
Katakura Industries Co., Ltd.39.01bn2.90bn71.66bn1.04k23.170.875112.391.8487.8287.821,179.692,325.400.27832.215.1037,506,730.002.192.352.823.3438.2537.757.878.322.71--0.107618.8116.62-2.048.0918.87-7.4610.76
Hunan Warrant Pharmaceutical Co Ltd29.14bn4.26bn71.99bn1.16k16.911.95--2.472.262.2615.4619.580.65551.458.571,248,132.008.5511.2110.1614.0562.7469.0013.0513.963.07--0.04518.0510.8418.5015.6019.0224.49--
Clinuvel Pharmaceuticals Limited9.19bn3.43bn72.19bn16.0021.363.7020.407.850.70140.70141.874.050.4496-0.10993.94--16.7818.8119.0521.04101.16102.6137.3139.008.3910.940.00437.4216.1524.7516.4414.4784.9614.87
Data as of Sep 20 2024. Currency figures normalised to Cuorips Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

0.24%Per cent of shares held by top holders
HolderShares% Held
Simplex Asset Management Co., Ltd.as of 05 Sep 202419.10k0.24%
Global X Japan Co., Ltd.as of 06 Sep 2024300.000.00%
Data from 30 Jun 2024 - 12 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.